New antibody AK1967 tested in healthy men as potential shock therapy
NCT ID NCT06331884
First seen Feb 28, 2026 · Last updated Jun 19, 2026 · Updated 14 times
Summary
This Phase 1 study tested the safety and tolerability of a single intravenous dose of AK1967 (Procizumab) in 24 healthy male volunteers. AK1967 is an antibody that blocks a protein called DPP3, which may worsen blood pressure drops during cardiogenic shock. The study only looked at safety and how the drug moves through the body, not whether it works for shock.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Radboud University Medical Center
Nijmegen, Gelderland, 6525, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK1967 (Procizumab)
What this could lead to
If successful, this could pave the way for a new treatment for cardiogenic shock by blocking a protein that worsens blood pressure instability.
What could go wrong
This is a very early Phase 1 study in only 24 healthy men, so it does not test if the drug works for shock. Safety and dosing are the only goals, and unexpected side effects may still appear.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.